RxDoctor Payments Data

Christopher Zulawski

Nurse Practitioner · Amherst, NYNPI 1790848489

Payments from drug & device makers

$8,108in general payments, 2019–2025

Across 408 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Teva Pharmaceuticals USA, Inc.$620
  • Pfizer$582
  • Amneal Pharmaceuticals LLC$531
  • SK Life Science, Inc.$513
  • UCB, Inc.$394
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$8,108100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,108 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$14,704
Medicare patients
100
Services billed
203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate78$110,368
NuplazidPimavanserin Tartrate13$61,119
UbrelvyUbrogepant25$25,474
RytaryCarbidopa/Levodopa35$20,100
KeppraLevetiracetam11$16,885
Ajovy SyringeFremanezumab-Vfrm13$15,669
Aimovig AutoinjectorErenumab-Aooe19$13,513
Lacosamide80$9,027
Gabapentin666$7,846
Levetiracetam216$7,756
Sumatriptan31$7,361
Pregabalin297$6,601
Amitriptyline Hcl526$6,061
HorizantGabapentin Enacarbil12$6,024
Topiramate ErTopiramate12$5,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$582$110,36878 claims
Acadia Pharmaceuticals IncNuplazid$38$61,11913 claims
AbbVieUbrelvy$1,504$25,47425 claims
Amneal Pharmaceuticals LLCRytary$531$20,10035 claims
Upsher-smith Laboratories LLCTopiramate$81$1,251130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →